Latest Breaking News On - Vaccinology at ghent university - Page 1 : comparemela.com

Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836

Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Desmond jamesPaul willemsTrophic communicationsVaccinology at ghent universityLast patient visitAlexandre le vertChief medical officerT andb cellGhent university

Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836

Excellent safety continues to be observed in ongoing Phase 2a dose optimization study (OVX836-003) Phase 2a dose optimization study extended to elderly population cohort (OVX836-003)

Kostenloser wertpapierhandelDesmond jamesPaul willemsTrophic communicationsVaccinology at ghent universityOsivaxt cellAlexandre le vertChief medical officerDose optimization studyGhent universityCombination trialQuadrivalent influenza vaccineT andb cellMedia inquiries

Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology

Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Osivax, a biopharmaceutical company developing vaccines to protect against highly

United statesKostenloser wertpapierhandelDesmond jamesEuropean union horizonInnovation programTrophic communicationsVaccinology at ghent universityWorld vaccine congressStudy evaluatingNucleoprotein based influenzaAlexandre le vertVaccine congressGhent universityEuropean unionMedia inquiries